apoL1 Double Nickase Plasmid (h): sc-403137-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- apoL1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- apoL1 Double Nickase Plasmid (h) and apoL1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting APOL1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: apoL1 Antibody (A-3): sc-390440
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
apoL1 Double Nickase Plasmid (h) | sc-403137-NIC | 20 µg | $410.00 | |||
apoL1 Double Nickase Plasmid (h2) | sc-403137-NIC-2 | 20 µg | $410.00 |
APOL1 encodes apolipoprotein L1 (apoL1), a lipid-binding, interferon-inducible protein implicated in innate immune defense and cellular stress responses. apoL1 localizes to intracellular membranes and has been linked to regulation of vesicle trafficking, autophagy, and mitochondrial and lysosomal homeostasis, with downstream effects on cell survival pathways. Genetic variation in APOL1 is strongly associated with increased susceptibility to kidney disease phenotypes, motivating mechanistic studies in podocytes and other renal cell types. APOL1 is also investigated in the context of host–pathogen interactions and inflammatory signaling networks that modulate its expression and function.
apoL1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the APOL1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within APOL1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt APOL1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of APOL1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.